Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, Ji'nan, Shandong 250012, China.
Curr Med Chem. 2014 Mar;21(7):894-910. doi: 10.2174/09298673113206660264.
Among the numerous endogenous promoters of angiogenesis, vascular endothelia growth factor (VEGF) plays a leading role in angiogenesis, which has huge impact on proliferation, survival, migration and permeability of tumor cells. VEGF signal system also becomes remarkable anticancer targets, including VEGF, vascular endothelia growth factor receptor (VEGFR), and VEGF downstream signal pathways. So far, there has been many clinical or approved anticancer drugs that directly or indireactly interfere with VEGF signal system applied in the treatment of various tumors and other diseases associated with pathological angiogenesis. Various kinds of antiangiogenic agents which inhibit VEGF and VEGFR have been developed and discovered gradually, including antibodies, ribozymes and small molecule inhibitors. Meanwhile, the investigation into antiangiogenic agents which block certain signal proteins of VEGF downstream signal pathways attracts the attention of medicinal chemists and enriches the application of antiangiogenic agents. This review will interpret the mysterious VEGF signal system from its molecular structure and probe to the mechanism of the combination of VEGF and its receptors. Furthermore, the detail of VEGF signal pathways will be introduced comprehensively and methodically. In addition, some up-to-date clinical or approved anticancer agents will be clearly tabulated. The binding modes of different kinase inhibitors will be used to explain the SAR of the small molecule inhibitors. Finally, in order to make the readers master VEGF signal system completely, some novel targets and inhibitors which block the downstream signal pathways of VEGF are plainly stated.
在众多内源性血管生成促进剂中,血管内皮生长因子(VEGF)在血管生成中起主导作用,对肿瘤细胞的增殖、存活、迁移和通透性有巨大影响。VEGF 信号系统也成为显著的抗癌靶点,包括 VEGF、血管内皮生长因子受体(VEGFR)和 VEGF 下游信号通路。迄今为止,已经有许多直接或间接干扰 VEGF 信号系统的临床或批准的抗癌药物应用于各种肿瘤及其他与病理性血管生成相关疾病的治疗。各种抑制 VEGF 和 VEGFR 的抗血管生成药物逐渐被开发和发现,包括抗体、核酶和小分子抑制剂。同时,阻断 VEGF 下游信号通路中某些信号蛋白的抗血管生成药物的研究引起了药物化学家的关注,并丰富了抗血管生成药物的应用。本文从分子结构上阐释了神秘的 VEGF 信号系统,并探讨了 VEGF 与其受体结合的机制。此外,还全面系统地介绍了 VEGF 信号通路的详细信息。另外,还明确列出了一些最新的临床或批准的抗癌药物。不同激酶抑制剂的结合模式将用于解释小分子抑制剂的 SAR。最后,为了使读者全面掌握 VEGF 信号系统,本文还明确阐述了阻断 VEGF 下游信号通路的一些新靶点和抑制剂。